IL159015A0 - Polypeptides, their preparation and use - Google Patents

Polypeptides, their preparation and use

Info

Publication number
IL159015A0
IL159015A0 IL15901501A IL15901501A IL159015A0 IL 159015 A0 IL159015 A0 IL 159015A0 IL 15901501 A IL15901501 A IL 15901501A IL 15901501 A IL15901501 A IL 15901501A IL 159015 A0 IL159015 A0 IL 159015A0
Authority
IL
Israel
Prior art keywords
polypeptides
preparation
Prior art date
Application number
IL15901501A
Other languages
English (en)
Original Assignee
Genset Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset Sa filed Critical Genset Sa
Publication of IL159015A0 publication Critical patent/IL159015A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
IL15901501A 2001-05-25 2001-08-06 Polypeptides, their preparation and use IL159015A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29357401P 2001-05-25 2001-05-25
US29869801P 2001-06-15 2001-06-15
US30227701P 2001-06-29 2001-06-29
US30545601P 2001-07-13 2001-07-13
PCT/IB2001/001715 WO2002094864A2 (fr) 2001-05-25 2001-08-06 Adnc et proteines humaines, ainsi que leurs utilisations

Publications (1)

Publication Number Publication Date
IL159015A0 true IL159015A0 (en) 2004-05-12

Family

ID=27501598

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15901501A IL159015A0 (en) 2001-05-25 2001-08-06 Polypeptides, their preparation and use

Country Status (7)

Country Link
US (10) US7074901B2 (fr)
EP (1) EP1390497A2 (fr)
JP (1) JP2005508141A (fr)
AU (1) AU2001286171B2 (fr)
CA (1) CA2448253A1 (fr)
IL (1) IL159015A0 (fr)
WO (1) WO2002094864A2 (fr)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE529444T1 (de) 1994-01-11 2011-11-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
US6494879B2 (en) 1998-10-15 2002-12-17 Scimed Life Systems, Inc. Treating urinary retention
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US20050271701A1 (en) * 2000-03-15 2005-12-08 Orbus Medical Technologies, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20160287708A9 (en) * 2000-03-15 2016-10-06 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US7317075B2 (en) * 2000-07-20 2008-01-08 Genentech, Inc. PRO21384 polypeptides
US20030100723A1 (en) * 2000-07-26 2003-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE10054055A1 (de) 2000-10-31 2002-05-23 Nmi Univ Tuebingen Verfahren zur Analyse von Proteinen
US7054758B2 (en) 2001-01-30 2006-05-30 Sciona Limited Computer-assisted means for assessing lifestyle risk factors
US20070015144A9 (en) * 2001-05-25 2007-01-18 Genset, S.A. Human cDNAs and proteins and uses thereof
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
EP1448772B1 (fr) * 2001-11-30 2007-07-18 Applied Research Systems ARS Holding N.V. Procedes pour augmenter les niveaux d'expression du recepteur du tnf
US7618788B2 (en) * 2002-05-10 2009-11-17 Millipore Corporation Proteome epitope tags and methods of use thereof in protein modification analysis
ATE488530T1 (de) * 2002-06-19 2010-12-15 Raven Biotechnologies Inc Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
US20040049484A1 (en) * 2002-09-11 2004-03-11 Hamano Life Science Research Foundation Method and apparatus for separating and extracting information on physiological functions
WO2004054517A2 (fr) * 2002-12-13 2004-07-01 Mediomics, Llc Compositions et methodes d'inhibition de la croissance des tumeurs et des metastases
DK1599222T3 (da) * 2003-01-08 2009-04-27 Novartis Vaccines & Diagnostic Stabiliserede vandige pr parater omfattende v vsfaktorvej-inhibitor (TFPI) eller v vsfaktorvej-inhibitorvariant
ES2356910T3 (es) * 2003-01-17 2011-04-14 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Construcciones para la expresión inducible de arn de interferencia pequeño (arns) para el silenciamiento génico seleccionado.
CA2489208C (fr) * 2003-02-24 2012-11-06 Morinaga Milk Industry Co., Ltd. Agent suppresseur de l'interleukine 6
DK2360475T3 (da) * 2003-03-27 2020-01-06 Childrens Hospital Med Ct Fremgangsmåde og kit til detektion af tidlig indtræden af renal tubulær celleskade
US7134459B2 (en) * 2003-06-12 2006-11-14 Symyx Technologies, Inc. Methods and apparatus for mixing powdered samples
PL2520654T3 (pl) 2003-08-26 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych
EP1519194A1 (fr) * 2003-09-24 2005-03-30 Roche Diagnostics GmbH L'utilisation de GFAP pour identifier une hémorragie intracérébrale
US20060286084A1 (en) * 2003-09-30 2006-12-21 Yoshikazu Morita Agent for promoting osteogenesis and/or inhibiting bone resorption
MXPA06005219A (es) 2003-11-12 2007-01-19 Univ Colorado Regents Composiciones y metodos para la regulacion del factor-alfa de necrosis tumoral.
US7332179B2 (en) 2003-12-12 2008-02-19 Kimberly-Clark Worldwide, Inc. Tissue products comprising a cleansing composition
EP1730286A4 (fr) * 2004-03-04 2007-09-05 Massachusetts Inst Technology Traitement anticancereux a base d'adn
WO2005092381A1 (fr) * 2004-03-25 2005-10-06 Centocor, Inc. Utilisation d'antagonistes de l'inducteur de metalloproteinase dans la matrice extracellulaire pour le traitement de maladies associees a un angiogenese excessive
EP1614755A1 (fr) * 2004-07-07 2006-01-11 ARTEMIS Pharmaceuticals GmbH Transgénèse ciblée de cassettes d'expression de shh RNA (Short hairpin RNA) par échange de cassette moyennant une récombinase
EP3489257A1 (fr) 2004-07-23 2019-05-29 Acceleron Pharma Inc. Polypeptides du récepteur actrii, procédés et compositions
IL163453A0 (en) * 2004-08-10 2009-02-11 Yeda Res & Dev Enzyme inhibitor in leukemia
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
US9145582B2 (en) * 2004-09-22 2015-09-29 The Trustees Of The University Of Pennsylvania Microarray techniques for nucleic acid expression analyses
CA2587775A1 (fr) 2004-11-22 2006-06-01 Dyax Corp. Therapies inhibitrices de la plasmine
US8172855B2 (en) 2004-11-24 2012-05-08 Abdou M S Devices and methods for inter-vertebral orthopedic device placement
US7642395B2 (en) 2004-12-28 2010-01-05 Kimberly-Clark Worldwide, Inc. Composition and wipe for reducing viscosity of viscoelastic bodily fluids
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
WO2006122187A2 (fr) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Traitement et evaluation des troubles inflammatoires
US20060265352A1 (en) * 2005-05-20 2006-11-23 International Business Machines Corporation Methods and apparatus for information integration in accordance with web services
JP2009501002A (ja) * 2005-06-07 2009-01-15 ザ ロックフェラー ユニバーシティ 膵臓β細胞増殖の刺激方法
WO2007019522A2 (fr) * 2005-08-04 2007-02-15 Carlos Lopez Inversion de troubles naissants chez l'adulte avec des facteurs de simulation d'une colonie de granulocytes
EP2781222B1 (fr) 2005-11-23 2017-08-02 Acceleron Pharma, Inc. Antagonistes de l'activine-actriia destinés à être utilisés pour la promotion de la croissance osseuse
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP1987360B1 (fr) * 2006-01-27 2012-03-07 Tripath Imaging, Inc. Méthodes permettant d'identifier des patientes présentant un risque accru d'être atteintes d'un cancer de l'ovaire et compositions associées
US8273005B2 (en) * 2006-02-02 2012-09-25 Samy Abdou Treatment of pain, neurological dysfunction and neoplasms using radiation delivery catheters
US7855057B2 (en) * 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
EP2010917B1 (fr) 2006-04-10 2012-06-27 Trustees of Boston University Biomarqueur de mélanome et procédés d'utilisation
CN105418751B (zh) * 2006-06-16 2019-03-05 肿瘤疗法·科学股份有限公司 来自sparc的癌排斥抗原肽以及含有该肽的药物
US20100284933A1 (en) * 2006-10-16 2010-11-11 Biogen Idec Ma Inc. Biomarkers of Multiple Sclerosis
AU2007325872B2 (en) * 2006-11-08 2012-12-13 Macrogenics West, Inc. TES7 and antibodies that bind thereto
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
WO2008076437A2 (fr) * 2006-12-18 2008-06-26 Acceleron Pharma Inc. Antagonistes de l'activine-actrii et ses utilisations pour accroître les niveaux de globules rouges
CA2677007A1 (fr) * 2007-02-01 2008-08-07 Acceleron Pharma Inc. Antagonistes de l'activine-actriia et leurs utilisations dans le traitement ou la prevention du cancer du sein
TW201803890A (zh) * 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2481415B1 (fr) 2007-02-09 2019-09-11 Acceleron Pharma Inc. Compositions comprenant des antagonistes Activin-ActRIIA
JP5572284B2 (ja) 2007-02-27 2014-08-13 Ｊｘ日鉱日石エネルギー株式会社 冷凍機油および冷凍機用作動流体組成物
US20080261298A1 (en) * 2007-04-23 2008-10-23 Olympus American Inc. Method and device for the multiplex analysis of cells and tissues
EP3127549B1 (fr) 2007-06-22 2019-12-18 Children's Medical Center Corporation Procédés et utilisations d'un fragment de saposine a
JP2010539236A (ja) 2007-09-18 2010-12-16 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用
EP3381445B1 (fr) 2007-11-15 2023-10-25 Amgen Inc. Formulation aqueuse d'anticorps stabilisée par des antioxydants pour administration parentérale
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
KR20110031951A (ko) * 2008-06-26 2011-03-29 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
CN102131822A (zh) * 2008-06-26 2011-07-20 阿塞勒隆制药公司 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法
GB0813123D0 (en) * 2008-07-17 2008-08-27 Symbian Software Ltd Method of searching
TWI354789B (en) * 2008-07-18 2011-12-21 Univ Kaohsiung Medical Il-8 as biomarker for the detection of urolithiasi
WO2010011860A1 (fr) 2008-07-23 2010-01-28 Diabetomics, Llc Procédé de détection du pré-diabète et du diabète
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
AU2010204985A1 (en) * 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
JP5912078B2 (ja) 2009-06-08 2016-04-27 アクセルロン ファーマ， インコーポレイテッド 熱発生性脂肪細胞を増加させるための方法
EP3290439B1 (fr) 2009-06-12 2020-09-02 Acceleron Pharma Inc. Protéines de fusion actriib-fc tronquées
AU2010282340B2 (en) 2009-08-13 2016-12-22 The Johns Hopkins University Methods of modulating immune function
WO2011056896A1 (fr) * 2009-11-03 2011-05-12 Acceleron Pharma Inc. Procédés de traitement de la stéatose hépatique
EP3332796A1 (fr) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Protéines actriib et variants et leurs utilisations se rapportant à l'induction de l'utrophine pour une thérapie de la dystrophie musculaire
US8764806B2 (en) 2009-12-07 2014-07-01 Samy Abdou Devices and methods for minimally invasive spinal stabilization and instrumentation
EP2513137B1 (fr) 2009-12-17 2018-02-28 Children's Medical Center Corporation Peptides dérivés de saposine a et utilisations de ceux-ci
CA2812194C (fr) 2010-09-17 2022-12-13 President And Fellows Of Harvard College Analyse de genomique fonctionnelle pour caracterisation de l'utilite et de l'innocuite de cellules souches pluripotentes
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
EP2723865B1 (fr) 2011-06-21 2019-03-27 Alnylam Pharmaceuticals, Inc. PROCÉDÉS DE DÉTERMINATION DE L'ACTIVITÉ DU RNAi CHEZ UN SUJET
KR20200044138A (ko) 2011-06-24 2020-04-28 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
CN103765212A (zh) 2011-06-27 2014-04-30 杰克逊实验室 治疗癌症和自体免疫性疾病的方法和组合物
US8845728B1 (en) 2011-09-23 2014-09-30 Samy Abdou Spinal fixation devices and methods of use
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
KR102035877B1 (ko) 2011-11-14 2019-10-23 알파시그마 에스.피.에이. 우울증이 있는 대상체를 위한 치료 양생법 선택을 위한 검정법 및 치료 방법
CA2860226C (fr) 2011-12-22 2022-10-18 Randolph S. Watnick Peptides derives de saposine a et utilisations de ceux-ci
JP2015504675A (ja) 2012-01-10 2015-02-16 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１アンチトリプシン融合分子の組成物、方法、及び使用
US20130269537A1 (en) 2012-04-16 2013-10-17 Eugenio Minvielle Conditioning system for nutritional substances
US20130226240A1 (en) 2012-02-22 2013-08-29 Samy Abdou Spinous process fixation devices and methods of use
US20130269538A1 (en) 2012-04-16 2013-10-17 Eugenio Minvielle Transformation system for nutritional substances
US10219531B2 (en) 2012-04-16 2019-03-05 Iceberg Luxembourg S.A.R.L. Preservation system for nutritional substances
US9541536B2 (en) 2012-04-16 2017-01-10 Eugenio Minvielle Preservation system for nutritional substances
US20150027950A1 (en) * 2012-03-27 2015-01-29 Marv Enterprises, LLC Treatment for atherosclerosis
EP3492095A1 (fr) 2012-04-01 2019-06-05 Technion Research & Development Foundation Limited Peptides d'inducteur de métalloprotéinase de matrice extracellulaire (emmprin) et anticorps de liaison
US9702858B1 (en) 2012-04-16 2017-07-11 Iceberg Luxembourg S.A.R.L. Dynamic recipe control
US9069340B2 (en) 2012-04-16 2015-06-30 Eugenio Minvielle Multi-conditioner control for conditioning nutritional substances
US20140069838A1 (en) 2012-04-16 2014-03-13 Eugenio Minvielle Nutritional Substance Label System For Adaptive Conditioning
US9121840B2 (en) 2012-04-16 2015-09-01 Eugenio Minvielle Logistic transport system for nutritional substances
US9080997B2 (en) 2012-04-16 2015-07-14 Eugenio Minvielle Local storage and conditioning systems for nutritional substances
US9429920B2 (en) 2012-04-16 2016-08-30 Eugenio Minvielle Instructions for conditioning nutritional substances
US9460633B2 (en) 2012-04-16 2016-10-04 Eugenio Minvielle Conditioner with sensors for nutritional substances
US9171061B2 (en) 2012-04-16 2015-10-27 Eugenio Minvielle Local storage and conditioning systems for nutritional substances
US9564064B2 (en) 2012-04-16 2017-02-07 Eugenio Minvielle Conditioner with weight sensors for nutritional substances
US9072317B2 (en) 2012-04-16 2015-07-07 Eugenio Minvielle Transformation system for nutritional substances
US9436170B2 (en) 2012-04-16 2016-09-06 Eugenio Minvielle Appliances with weight sensors for nutritional substances
US9528972B2 (en) 2012-04-16 2016-12-27 Eugenio Minvielle Dynamic recipe control
US8733631B2 (en) 2012-04-16 2014-05-27 Eugenio Minvielle Local storage and conditioning systems for nutritional substances
US9414623B2 (en) * 2012-04-16 2016-08-16 Eugenio Minvielle Transformation and dynamic identification system for nutritional substances
US9198767B2 (en) 2012-08-28 2015-12-01 Samy Abdou Devices and methods for spinal stabilization and instrumentation
US9320617B2 (en) 2012-10-22 2016-04-26 Cogent Spine, LLC Devices and methods for spinal stabilization and instrumentation
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
JP6697380B2 (ja) 2013-06-10 2020-05-20 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 多能性幹細胞の有用性および安全性を特徴付けるための初期発生ゲノムアッセイ
US10790062B2 (en) 2013-10-08 2020-09-29 Eugenio Minvielle System for tracking and optimizing health indices
AU2015212341A1 (en) 2014-02-03 2016-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of Casein kinase I inhibitors for depleting stem cells
WO2015164743A2 (fr) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Suppresseur de tumeur et biomarqueurs oncogènes prédictifs de réponse à un inhibiteur de point de contrôle anti-immunitaire
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
CA2952285A1 (fr) 2014-06-19 2015-12-23 Memorial Sloan-Kettering Cancer Center Biomarqueurs de la reponse aux inhibiteurs d'ezh2
EP3808756A1 (fr) 2014-07-17 2021-04-21 The Trustees of The University of Pennsylvania Procédés permettant d'utiliser des exosomes pour surveiller l'état d'un organe transplanté
USD762081S1 (en) 2014-07-29 2016-07-26 Eugenio Minvielle Device for food preservation and preparation
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
US10806773B2 (en) 2014-10-09 2020-10-20 Dana-Farber Cancer Institute, Inc. Multiple-variable IL-2 dose regimen for treating immune disorders
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
TWI730949B (zh) 2014-12-03 2021-06-21 美商西建公司 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途
AU2016229238B2 (en) 2015-03-06 2022-06-02 Dana-Farber Cancer Institute, Inc. PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
KR101713421B1 (ko) * 2015-07-03 2017-03-09 울산대학교 산학협력단 뇌신경질환의 진단 또는 치료용 조성물
US10857003B1 (en) 2015-10-14 2020-12-08 Samy Abdou Devices and methods for vertebral stabilization
US10464977B2 (en) * 2016-04-11 2019-11-05 University Of Maryland, Baltimore Histatin-5 based synthetic peptides and uses thereof
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
ES3033182T3 (en) 2016-09-20 2025-07-31 Dana Farber Cancer Inst Inc Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
US10744000B1 (en) 2016-10-25 2020-08-18 Samy Abdou Devices and methods for vertebral bone realignment
US10973648B1 (en) 2016-10-25 2021-04-13 Samy Abdou Devices and methods for vertebral bone realignment
EP3532496A1 (fr) 2016-10-28 2019-09-04 Banyan Biomarkers, Inc. Anticorps dirigés contre l'ubiquitine c-terminale hydrolase l1 (uch-l1) et la protéine acide fibrillaire gliale (gfap) et méthodes associées
US11820822B2 (en) 2017-06-06 2023-11-21 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
US20200339987A1 (en) 2017-11-09 2020-10-29 Alnylam Pharmaceuticals, Inc. Assays and methods for determining expression of the lect2 gene
CA3090305A1 (fr) 2018-02-28 2019-09-06 Dana-Farber Cancer Institute, Inc. Methodes de traitement du cancer a l'aide de combinaisons d'agents de blocage anti-btnl2 et points de controle immunitaires
US12103972B2 (en) 2018-04-06 2024-10-01 Dana-Farber Cancer Institute, Inc. KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof
US11179248B2 (en) 2018-10-02 2021-11-23 Samy Abdou Devices and methods for spinal implantation
US12227548B2 (en) 2018-11-19 2025-02-18 Dana-Farber Cancer Institute, Inc. Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
US12297244B2 (en) 2019-06-05 2025-05-13 Rensselaer Polytechnic Institute Systems and methods for inhibiting γ-secretase production of amyloid-β peptides
US12018279B2 (en) 2019-10-18 2024-06-25 The Trustees Of The University Of Pennsylvania Micro-engineered models of the human eye and methods of use
CN111161800B (zh) * 2019-12-30 2021-05-07 云舟生物科技（广州）有限公司 基因载体的序列诊断方法、系统、存储介质及电子设备
EP4093513A4 (fr) 2020-01-24 2024-05-08 Dana-Farber Cancer Institute, Inc. Utilisations de biomarqueurs pour améliorer une immunothérapie
US20240024377A1 (en) 2020-10-29 2024-01-25 Evelo Biosciences, Inc. Compositions comprising spirulina components
CN112716971B (zh) * 2021-01-19 2022-01-25 苏州大学 lncRNA XR_595534.2在制备治疗或预防慢性疼痛的药物中的应用
AU2022229805B2 (en) 2021-03-02 2026-02-05 Dana-Farber Cancer Institute, Inc. Methods of treating red blood cell disorders
US12467917B2 (en) 2021-03-16 2025-11-11 California Institute Of Technology Reconstructing human early embryogenesis in vitro with pluripotent stem cells
EP4074820A1 (fr) 2021-04-16 2022-10-19 The Trustees of The University of Pennsylvania Modèles micro-façonnés de l' il humain et procédés d'utilisation
WO2022251166A2 (fr) 2021-05-25 2022-12-01 Evelo Biosciences, Inc. Compositions bactériennes comprenant de l'hémoglobine de soja
WO2022261183A2 (fr) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions et procédés de traitement et/ou d'identification d'un agent pour le traitement de cancers intestinaux
EP4440594A2 (fr) 2021-11-29 2024-10-09 Dana-Farber Cancer Institute, Inc. Méthodes et compositions pour moduler riok2
IL313064A (en) 2021-12-14 2024-07-01 California Inst Of Techn Methods, cultures and devices for producing embryos from stem cells in vitro
GB202208171D0 (en) 2022-06-01 2022-07-13 Institute Of Cancer Res Method
JP7437558B1 (ja) 2023-07-20 2024-02-22 株式会社ファーマフーズ 情報処理装置、情報処理方法、およびプログラム
WO2025034542A1 (fr) 2023-08-04 2025-02-13 Cornell University Panel de signature génique prédisant une réponse cancéreuse à un blocage de point de contrôle immunitaire et radiothérapie
WO2025169718A1 (fr) * 2024-02-09 2025-08-14 富士レビオ株式会社 Polypeptide multimérisé, bandelette immunochromatographique, dispositif immunochromatographique, kit immunochromatographique et procédé de détection d'analyte

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) * 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4657760A (en) * 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4444887A (en) * 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
FI831484A7 (fi) * 1982-05-05 1983-11-06 Genentech Inc Ihmiskudoksen plasminogeenien aktivaattori.
US4716111A (en) * 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4725576A (en) * 1983-12-29 1988-02-16 Research Foundation Of State University Of New York Fungicidal polypeptide compositions containing L-histidine and methods for use therefore
US4609725A (en) * 1984-10-09 1986-09-02 Merck & Co., Inc. Cardiac atrial peptides
AU6131086A (en) * 1985-07-05 1987-01-30 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5340934A (en) * 1989-11-03 1994-08-23 The United States Of Americas As Represented By The Secretary Of Health & Human Services CDNA sequences of human bone matrix proteins
US5817629A (en) 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
GB9216558D0 (en) 1992-08-04 1992-09-16 British Bio Technology Modified proteases
WO1999014234A2 (fr) * 1997-09-17 1999-03-25 Genentech, Inc. Stimulation ou inhibition de l'angiogenese et de la cardiovascularisation
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
AU6383396A (en) 1995-06-07 1996-12-30 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
US6221645B1 (en) 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US20060009633A9 (en) * 1997-11-13 2006-01-12 Genset, S.A. Complementary DNAs encoding proteins with signal peptides
EP1042725A1 (fr) * 1997-12-16 2000-10-11 President And Fellows Of Harvard College Mimetiques a coordonnees d'endostatine generes par ordinateur
ATE440951T1 (de) 1997-12-17 2009-09-15 Serono Genetics Inst Sa Verlängerte cdns, die für sekretierte proteine kodieren
AU2978899A (en) 1998-03-03 1999-09-20 Abgenix, Inc. Cd147 binding molecules as therapeutics
JP2002511259A (ja) * 1998-04-09 2002-04-16 ジェンセット ５’ｅｓｔおよびコードされるヒトタンパク質
US6184241B1 (en) 1998-08-24 2001-02-06 Kansas State University Research Foundation Aspartic protease inhibitors
KR20070013361A (ko) 1998-09-24 2007-01-30 파마시아 앤드 업존 캄파니 엘엘씨 알츠하이머병 세크레타제
WO2001053455A2 (fr) 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides associes
WO2000035473A2 (fr) * 1998-12-18 2000-06-22 Scios Inc. Methodes de detection et d'utilisation de genes exprimes de façon differentielle dans des maladies
JP4653318B2 (ja) 1999-02-10 2011-03-16 エラン ファーマシューティカルズ，インコーポレイテッド βセクレターゼ酵素組成物および方法
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2000058479A1 (fr) 1999-03-26 2000-10-05 Amgen Inc. Genes et polypeptides beta secretase
DE19915485A1 (de) * 1999-04-07 2000-10-19 Hugo A Katus Therapie der Herzinsuffizienz
CA2374346C (fr) 1999-06-28 2010-06-22 Jordan J. N. Tang Inhibiteurs de memapsine 2 et son utilisation
JP2003507033A (ja) * 1999-08-13 2003-02-25 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １３個のヒト結腸タンパク質および結腸癌に関連するタンパク質
CA2385743A1 (fr) * 1999-09-28 2001-04-05 Universitat Zurich Facteurs ayant une activite de liaison au prion dans du serum ou du plasma et agents permettant de detecter l'encephalopathie spongiforme transmissible
WO2002000677A1 (fr) * 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps

Also Published As

Publication number Publication date
WO2002094864A2 (fr) 2002-11-28
US7074901B2 (en) 2006-07-11
AU2001286171B2 (en) 2008-01-10
US20030027248A1 (en) 2003-02-06
US6989262B2 (en) 2006-01-24
US20030092011A1 (en) 2003-05-15
US6794363B2 (en) 2004-09-21
US7094876B2 (en) 2006-08-22
US7291495B2 (en) 2007-11-06
US7122629B2 (en) 2006-10-17
US20030096247A1 (en) 2003-05-22
US20030170628A1 (en) 2003-09-11
EP1390497A2 (fr) 2004-02-25
AU2001286171B8 (en) 2002-12-03
US20030198954A1 (en) 2003-10-23
JP2005508141A (ja) 2005-03-31
US20060211090A1 (en) 2006-09-21
US20050026182A1 (en) 2005-02-03
US20030157485A1 (en) 2003-08-21
CA2448253A1 (fr) 2002-11-28
US20070292885A1 (en) 2007-12-20
US7074571B2 (en) 2006-07-11
US20030027161A1 (en) 2003-02-06
WO2002094864A3 (fr) 2003-06-19
US7005500B2 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
HUP0500989A2 (en) Animicrobial polypeptides and their uses
TWI371450B (en) Novel substituted dihydro 3-halo-1h-pyrazole-5-carboxylates,their preparation and use
HUP0401335A3 (en) Herbicidal pyridylpropynyloxyphenyl derivatives, preparation and use thereof
HUP0401461A3 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
HUP0301243A3 (en) Herbicidal substituted pyridine-ketones, preparation and use thereof
HUP0500060A3 (en) Human coagulation factor vii polypeptides
AU2002359126A8 (en) Benzodiazepine derivatives, preparation thereof and use thereof
AU2002359123A8 (en) Benzodiazepine derivatives, preparation thereof and use thereof
IL158397A0 (en) Polypeptides, their preparation and their use
IL159872A0 (en) Gmg-2 polypeptides and their use
TWI318974B (en) Acylaminothiazole derivatives, their preparation and their therapeutic use
SI1043307T1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use
HUP0401092A3 (en) 5-halogen-6-phenyl-7-fluoralkylamino-triazolopyrimidines as fungicides, preparation and use thereof
IL161235A0 (en) Fsh composition, its preparation and use
HUP0303260A3 (en) Agrochemical formulations, preparation and use thereof
HUP0401157A3 (en) Methyl-thieno-benzodiazepine lyophilized formulation, its preparation and use
HUP0600238A3 (en) Benzothiazole- and benzoxazole-4,7-dione derivatives and their use
GB0217548D0 (en) Four human zinc-finger-containing proteins:MDZ3.MDZ4,MDZ7 and MDZ12
PL365342A1 (en) Mikanolide derivatives, their preparation and therapeutic uses
HUP0203678A3 (en) Nitro-sulfobenzamide-derivatives, preparation and use thereof
SI1043306T1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and use
IL161234A0 (en) Ngzipa, ngzipd, pgzipa and pgzipd polynucleotides and polypeptides and uses thereof
AU2003299336A8 (en) Diphosphines, preparation and uses thereof
AU2001280464A1 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof
IL158435A0 (en) Polypeptides, derivatives and uses thereof